TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas

  • STATUS
    Recruiting
  • days left to enroll
    5
  • participants needed
    140
  • sponsor
    National Cancer Institute (NCI)
Updated on 4 October 2022
cancer
lymphoma
nitrosoureas
measurable disease
metastasis
neutrophil count
liver metastasis
tumor cells
blood transfusion
chemotherapy regimen
mitomycin
cancer treatment
cancer chemotherapy
temozolomide
solid tumour
bisphosphonate
secondary malignant neoplasm of liver

Summary

Background
  • TRC102 is a new cancer treatment drug that may help improve the results of chemotherapy. It blocks tumor cells' attempts to repair damaged DNA, which may allow chemotherapy to kill the cells more easily. Researchers want to see how well it works with temozolomide, a chemotherapy drug that is designed to damage tumor cell DNA. These drugs will be given to people who have advanced solid tumors or lymphomas that have not responded to earlier treatments.
    Objectives
  • To test the safety and effectiveness of TRC102 and temozolomide for advanced solid tumors and lymphomas.
    Eligibility
  • Individuals at least 18 years of age who have advanced solid tumors or lymphomas that have not responded to earlier treatments.
    Design
  • Participants will be screened with a physical exam and medical history. Blood and urine samples will be collected. Tumor samples may also be collected. The size and location of the tumors will be determined with imaging studies.
  • Participants will take TRC102 and temozolomide for 28-day cycles of treatment. They will take temozolomide and TRC 102 by mouth once a day on days 1-5. Participants will keep a diary to record doses and any side effects.
  • Treatment will be monitored with frequent blood tests and imaging studies. Tumor samples will also be collected.
  • Participants will continue their treatment as long as the cancer does not grow and there are no severe side effects.

Description

Background

-Base excision repair (BER) of DNA repair pathway has been implicated in resistance to

both alkylating and antimetabolite chemotherapy.

-TRC102 (methoxyamine HCl) acts through a novel mechanism to inhibit BER and has

demonstrated the ability to potentiate the activity of the alkylating agent temozolomide

(TMZ), in vitro and in vivo. We hypothesize that TRC102 can be safely co-administered

with TMZ and would potentiate DNA damage caused by TMZ, resulting in antitumor

responses.

-Based on responses measured during the Phase I portion of the trial, we will further

explore the efficacy of this combination in patients with metastatic colon carcinoma, nonsmall

cell lung cancer (NSCLC), and granulosa cell ovarian cancer

Primary Objective:

-To establish the safety, tolerability, and maximum tolerated dose (MTD) of oral TRC102

in combination with oral TMZ in patients with refractory solid tumors

-Evaluate the pharmacokinetic (PK) profile of oral TRC102 when administered in

combination with TMZ.

-To explore the response rate of this combination in patients with colon cancer, NSCLC,

and granulosa cell ovarian cancer

Secondary Objective:

  • To explore the progression free survival rate of this combination in patients with colon

cancer, NSCLC, and granulosa cell ovarian cancer

Exploratory Objectives:

  • Investigate tumor genomic and transcriptomic alterations potentially associated with sensitivity and/or the development of resistance to TRC102 and temozolomide.
  • Determine the effects of the study treatment on the level of histone gamma-H2AX in circulating tumor cells (CTCs) and tumor and correlate the gamma-H2AX response in tumor and CTCs
  • Determine the effects of the study treatment on the levels of cleaved caspase 3, epithelial- mesenchymal transition, and APE in tumor and CTCs
  • Determine and characterize the effects of study treatment on erythrocytes
  • Characterize the clinical presentation of hemolysis observed in earlier study subjects and explore the possible mechanisms
    Eligibility

-Phase I: histologically confirmed solid tumors that have progressed on standard therapy

known to prolong survival or for which no standard treatment options exist

-Phase II: histologically confirmed adenocarcinoma of the colon post at least two lines of

therapy, NSCLC post at least two lines of therapy, or granulosa cell ovarian cancer post at

least one line of therapy

  • No major surgery, radiation, or chemotherapy within 4 weeks prior to entering the study
  • Adequate organ function
  • Healthy adult volunteers greater than or equal to 18 years of age will be consented to donate research blood

Please note: healthy adult volunteers will no longer be recruited to provide blood for this study as we will no longer perform the hemolysis analysis.

Study Design: Phase I

  • This is an open-label Phase I trial; traditional 3+3 design.
  • Oral TRC102 and oral TMZ will be administered daily, days 1-5 in 28-day cycles
  • Once the MTD is established, up to 15 additional patients will be enrolled at the MTD to

further evaluate that dose for PK and PD endpoints for evidence of DNA damage and

apoptosis.

-During the escalation phase, tumor biopsies will be optional. During the expansion phase,

(once MTD is reached), mandatory paired tumor biopsies will be pursued in the 15

additional patients enrolled to further evaluate PD endpoints.

Phase II

-This is a 3-arm Simon 2-stage design trial evaluating independently the response rate of

patients with colon, NSCLC, and granulosa cell ovarian cancer.

  • Patients with a body surface area (BSA) of greater than or equal to 1.6 m(2) will receive 125 mg of TRC 102 and 150 mg/m2 of TMZ PO qday x 5 every 28 days (DL6). Patients with a BSA of <1.6 m(2) will receive 100 mg of TRC 102 and 150 mg/m2 of TMZ PO qday x 5 every 28 days (DL5).. Each cycle will be 28 days.
  • The accrual ceiling for the Phase II portion is 75 patients.
  • Mandatory paired tumor biopsies will be pursued to further evaluate PD endpoints.

Details
Condition Lymphomas, Solid Tumors, NSCLC, Metastatic Colon Carcinoma, Granulosa Cell Ovarian Cancer
Treatment TRC 102
Clinical Study IdentifierNCT01851369
SponsorNational Cancer Institute (NCI)
Last Modified on4 October 2022

Eligibility

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note